JP2020529994A - 有機リン酸誘導体 - Google Patents
有機リン酸誘導体 Download PDFInfo
- Publication number
- JP2020529994A JP2020529994A JP2020505363A JP2020505363A JP2020529994A JP 2020529994 A JP2020529994 A JP 2020529994A JP 2020505363 A JP2020505363 A JP 2020505363A JP 2020505363 A JP2020505363 A JP 2020505363A JP 2020529994 A JP2020529994 A JP 2020529994A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538879P | 2017-07-31 | 2017-07-31 | |
| US62/538,879 | 2017-07-31 | ||
| US201862637960P | 2018-03-02 | 2018-03-02 | |
| US62/637,960 | 2018-03-02 | ||
| PCT/US2018/044389 WO2019027905A1 (en) | 2017-07-31 | 2018-07-30 | ORGANOPHOSPHATE DERIVATIVES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529994A true JP2020529994A (ja) | 2020-10-15 |
| JP2020529994A5 JP2020529994A5 (https=) | 2021-09-09 |
Family
ID=65234161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505363A Pending JP2020529994A (ja) | 2017-07-31 | 2018-07-30 | 有機リン酸誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11306111B2 (https=) |
| EP (1) | EP3661513A4 (https=) |
| JP (1) | JP2020529994A (https=) |
| CN (1) | CN111491634A (https=) |
| AU (1) | AU2018312224A1 (https=) |
| CA (1) | CA3071612A1 (https=) |
| WO (1) | WO2019027905A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11306111B2 (en) | 2017-07-31 | 2022-04-19 | January Therapeutics, Inc. | Organophosphate derivatives |
| EP3752511A4 (en) | 2018-01-10 | 2021-12-29 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| WO2019169323A1 (en) * | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
| JP2021534258A (ja) * | 2018-08-20 | 2021-12-09 | キュア・バイオファーマ・インコーポレイテッドCure Biopharma Inc. | ゲムシタビンプロドラッグ |
| AU2020263283B2 (en) * | 2019-04-22 | 2026-04-23 | Ligand Pharmaceuticals Incorporated | Cyclic phosphate compounds |
| GR1009958B (el) * | 2019-04-24 | 2021-03-18 | ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." | Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης |
| CN114206896B (zh) | 2019-07-17 | 2024-12-17 | 纽科利制药公司 | 环状脱氧核糖核苷酸化合物 |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| KR20220058890A (ko) * | 2019-09-10 | 2022-05-10 | 소니그룹주식회사 | 무선 통신 장치 및 방법 |
| CN115605492B (zh) | 2020-04-21 | 2025-09-16 | 配体制药股份有限公司 | 核苷酸前药化合物 |
| US12552820B2 (en) | 2020-04-21 | 2026-02-17 | Ligand Pharmaceuticals Incorporated | Benzyloxy phosph(on)ate compounds |
| AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130131008A1 (en) * | 2011-10-25 | 2013-05-23 | Board Of Regents, The University Of Texas System | Lipophilic monophosphorylated derivatives and nanoparticles |
| JP2013540129A (ja) * | 2010-10-06 | 2013-10-31 | ニューカナー、バイオメッド、リミテッド | がん治療で使用するためのゲムシタビンのアミド亜リン酸エステル誘導体 |
| JP2016538252A (ja) * | 2013-10-11 | 2016-12-08 | アラ・ケム・エルエルシー | 置換された（ｓ）−（２ｒ，３ｒ，５ｒ）−３−ヒドロキシ−（５−ピリミジン−１−イル）テトラヒドロフラン−２−イルメチルアリールホスホロアミデート |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2874016B1 (fr) | 2004-06-30 | 2006-11-24 | Centre Nat Rech Scient Cnrse | Nanoparticules de derives de la gemcitabine |
| US20090118223A1 (en) | 2005-08-12 | 2009-05-07 | Erion Mark D | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives |
| MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| CN101732258B (zh) | 2008-11-19 | 2013-12-25 | 复旦大学附属华山医院 | 一种用于肿瘤化疗的纳米微球制剂及其制备方法 |
| KR20140005998A (ko) | 2011-01-24 | 2014-01-15 | 안테리오스, 인코퍼레이티드 | 나노입자 조성물, 이의 제형, 및 그의 용도 |
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| CN103239733A (zh) | 2012-02-09 | 2013-08-14 | 复旦大学附属肿瘤医院 | 一种整合素靶向型载药白蛋白纳米粒制剂及其制备方法 |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| EP4378461A3 (en) | 2013-03-05 | 2024-09-11 | The Regents of University of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| KR20150047336A (ko) | 2013-10-24 | 2015-05-04 | 삼성전자주식회사 | 나노입자, 이를 제조하는 방법, 및 이의 용도 |
| JP6581100B2 (ja) * | 2014-02-06 | 2019-09-25 | リボサイエンス・エルエルシー | インフルエンザｒｎａ複製の阻害剤としての４’−ジフルオロメチル置換ヌクレオシド誘導体 |
| WO2015134334A1 (en) * | 2014-03-03 | 2015-09-11 | Suo Zucai | Gemcitabine analogs |
| LT3160476T (lt) | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
| TWI678373B (zh) | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | 硫代核苷衍生物或其鹽及醫藥組合物 |
| EP3303359B1 (en) | 2015-05-27 | 2024-11-06 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of cancer |
| CN104961786B (zh) | 2015-06-05 | 2018-09-25 | 苏州大学 | 基于吉西他滨结构的前体药物及其应用 |
| CN108601746B (zh) | 2016-01-08 | 2024-09-13 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
| US11306111B2 (en) | 2017-07-31 | 2022-04-19 | January Therapeutics, Inc. | Organophosphate derivatives |
| US20210007999A1 (en) | 2018-03-02 | 2021-01-14 | January Therapeutics, Inc. | Nanoparticle compositions |
| WO2019169323A1 (en) | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
| JP2021534258A (ja) | 2018-08-20 | 2021-12-09 | キュア・バイオファーマ・インコーポレイテッドCure Biopharma Inc. | ゲムシタビンプロドラッグ |
| WO2020041051A1 (en) | 2018-08-20 | 2020-02-27 | Cure Biopharma Inc. | Gemcitabine prodrugs |
| WO2020223530A1 (en) | 2019-04-30 | 2020-11-05 | Cure Biopharma Inc. | Gemcitabine prodrugs |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
-
2018
- 2018-07-30 US US16/635,469 patent/US11306111B2/en active Active
- 2018-07-30 EP EP18840263.0A patent/EP3661513A4/en not_active Withdrawn
- 2018-07-30 AU AU2018312224A patent/AU2018312224A1/en not_active Abandoned
- 2018-07-30 WO PCT/US2018/044389 patent/WO2019027905A1/en not_active Ceased
- 2018-07-30 CA CA3071612A patent/CA3071612A1/en active Pending
- 2018-07-30 JP JP2020505363A patent/JP2020529994A/ja active Pending
- 2018-07-30 CN CN201880063984.4A patent/CN111491634A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013540129A (ja) * | 2010-10-06 | 2013-10-31 | ニューカナー、バイオメッド、リミテッド | がん治療で使用するためのゲムシタビンのアミド亜リン酸エステル誘導体 |
| US20130131008A1 (en) * | 2011-10-25 | 2013-05-23 | Board Of Regents, The University Of Texas System | Lipophilic monophosphorylated derivatives and nanoparticles |
| JP2016538252A (ja) * | 2013-10-11 | 2016-12-08 | アラ・ケム・エルエルシー | 置換された（ｓ）−（２ｒ，３ｒ，５ｒ）−３−ヒドロキシ−（５−ピリミジン−１−イル）テトラヒドロフラン−２−イルメチルアリールホスホロアミデート |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF CONTROLLED RELEASE, vol. Vol. 169, No. 1-2, JPN6022034070, 2013, pages 17 - 27, ISSN: 0004850617 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111491634A (zh) | 2020-08-04 |
| WO2019027905A1 (en) | 2019-02-07 |
| AU2018312224A1 (en) | 2020-02-27 |
| US20200369695A1 (en) | 2020-11-26 |
| CA3071612A1 (en) | 2019-02-07 |
| EP3661513A1 (en) | 2020-06-10 |
| US11306111B2 (en) | 2022-04-19 |
| EP3661513A4 (en) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529994A (ja) | 有機リン酸誘導体 | |
| KR101728647B1 (ko) | 신규 화합물 및 치료 방법 | |
| EP2513114B1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| ES2974494T3 (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar las infecciones por ortomixovirus | |
| TWI797111B (zh) | 雙重magl及faah抑制劑 | |
| CN115843272A (zh) | Nek7激酶的抑制剂 | |
| KR101982951B1 (ko) | 신규한 유형의 시티딘 유도체 및 그의 용도 | |
| CN104066719B (zh) | 用作mogat-2抑制剂的苄基磺酰胺衍生物 | |
| JP2022506442A (ja) | トリフルオロメチル置換スルファミド系選択的ｂｃｌ－２阻害剤 | |
| JP2022532877A (ja) | Ｊａｋ阻害剤 | |
| JP7793763B2 (ja) | Ｔｙｋ２／ｊａｋ１シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法 | |
| KR102521320B1 (ko) | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 | |
| JP7005508B2 (ja) | ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体 | |
| JP7282104B2 (ja) | Ａｂｈｄ１２阻害剤並びにその製造及び使用方法 | |
| KR20170073699A (ko) | 신규한 유형의 시티딘 유도체 이량체 및 그의 용도 | |
| TWI652265B (zh) | 氮雜吲哚衍生物 | |
| ES2971502T3 (es) | Inhibidores de ABHD12 y procedimientos de producción y uso de los mismos | |
| HK40035089A (en) | Organophosphate derivatives | |
| HK40119293A (en) | Fused tricyclic pyridazinone compounds and prodrugs thereof useful to treat orthomyxovirus infections | |
| BR122023025728A2 (pt) | Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7hpirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus, seus usos para tratamento de influenza, composição farmacêutica, e combinação | |
| HK40042824B (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| HK40042824A (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| JPH1036383A (ja) | ４−ｎ−アシル−２−チオシトシンアラビノシドならびに該化合物を活性成分として含有する抗癌剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210727 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230313 |